- Kraig Biocraft Laboratories (KBLB, Financial) announces advancements in spider silk technology.
- New double hybrid production strain to increase silk production by over 25% monthly.
- Commercial deliveries set for H2 2025 to three major global brands.
Kraig Biocraft Laboratories (KBLB), a leading figure in the development of spider silk technology, has issued a shareholder letter highlighting significant strides in their production processes. The company has successfully developed a new transgenic spider silk production strain under its double hybrid system, promising to boost monthly silk production by more than 25%. This marks a crucial step forward in KBLB’s production capabilities, enhancing efficiency and robustness in silk production.
The company’s existing BAM-1 single hybrid system, launched in 2024, has demonstrated improvements in robustness and productivity, aligning closely with the quality standards of Chinese commercial silk hybrids. By Q1 2025, Kraig Biocraft has stockpiled hundreds of kilograms of spider silk cocoons, which will be included in future work-in-progress reports.
Looking ahead, KBLB is gearing up for commercial deliveries slated for the latter half of 2025. The company has secured commitments from three major global brands: a prominent luxury fashion label, a high-end performance sportswear company, and one of the top five athletic equipment manufacturers worldwide. These entities have shown intent through approved budgets or quotes to incorporate KBLB’s innovative spider silk into their product lines.
